Roche has received CE marking in the European Union for Contivue, its innovative Port Delivery Platform for administering Susvimo in the treatment of neovascular (wet) age-related macular degeneration (nAMD). The Contivue system comprises an implantable device and four supporting components to fill, insert, refill, and, if necessary, remove the implant through a streamlined outpatient procedure. Susvimo, a formulation of ranibizumab, is under evaluation by the European Medicines Agency for nAMD treatment.

Clinical data spanning seven years from the LADDER study demonstrated that patients treated with Contivue maintained stable visual acuity and retinal anatomy, experiencing minimal deterioration in vision, with approximately 95 per cent of patients sustaining therapy durability. Treatment frequency is significantly reduced, requiring only up to two refills per year, compared with conventional monthly intravitreal injections. In the United States, Contivue with Susvimo is already approved for nAMD, diabetic macular oedema (DME), and diabetic retinopathy.

Levi Garraway, Chief Medical Officer at Roche, noted that Susvimo gives patients living with nAMD the opportunity to preserve their vision with a much-reduced treatment burden. The continuous-delivery approach offers long-term clinical benefits, supported by robust follow-up results.

The approval of Contivue in Europe marks a significant milestone in the evolution of ophthalmic manufacturing and drug delivery systems. By offering durable, sustained dosages via a refillable implant, Roche is advancing both therapeutic outcomes and manufacturing efficiencies. The platform also holds potential for future application to additional molecules under development that may be delivered via the same manufacturing and implant system.